Verona Pharma plc (VRNA) DCF Valuation

Valoración de DCF de Verona Pharma PLC (VRNA)

GB | Healthcare | Biotechnology | NASDAQ
Verona Pharma plc (VRNA) DCF Valuation
  • ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
  • ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
  • ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
  • ✓ No Se Necesita Experiencia; Fáciles De Seguir

Verona Pharma plc (VRNA) Bundle

Get Full Bundle:
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

¡Agilice su análisis y mejore la precisión con nuestra calculadora DCF (vRNA)! Utilizando los datos reales de Verona Pharma y supuestos personalizables, esta herramienta le permite pronosticar, evaluar y evaluar (VRNA) al igual que un inversor experimentado.


Discounted Cash Flow (DCF) - (USD MM)

Year AY1
2019		 AY2
2020		 AY3
2021		 AY4
2022		 AY5
2023		 FY1
2024		 FY2
2025		 FY3
2026		 FY4
2027		 FY5
2028
Revenue .0 .0 50.3 .6 .0 .0 .0 .0 .0 .0
Revenue Growth, % 0 -100 0 -98.85 -100 -74.71 -74.71 -74.71 -74.71 -74.71
EBITDA -40.5 -60.1 -53.1 -84.6 -66.0 .0 .0 .0 .0 .0
EBITDA, % -1368177.88 100 -105.47 -14692.36 100 -20 -20 -20 -20 -20
Depreciation .6 .8 .8 .8 .9 .0 .0 .0 .0 .0
Depreciation, % 21782.69 100 1.57 138.86 100 80.31 80.31 80.31 80.31 80.31
EBIT -41.1 -60.9 -53.8 -85.4 -66.8 .0 .0 .0 .0 .0
EBIT, % -1389960.57 100 -107.05 -14831.22 100 -20 -20 -20 -20 -20
Total Cash 50.7 236.4 186.6 286.5 341.8 .0 .0 .0 .0 .0
Total Cash, percent 1.7 .0 .0 .0 .0 .0 .0 .0 .0 .0
Account Receivables .0 10.4 19.6 11.7 13.8
Account Receivables, % 0 100 38.96 2026.64 100
Inventories 4.4 5.7 5.1 3.1 .0 .0 .0 .0 .0 .0
Inventories, % 149091.71 100 10.09 545.63 100 82.02 82.02 82.02 82.02 82.02
Accounts Payable 2.4 .2 12.6 3.7 4.4 .0 .0 .0 .0 .0
Accounts Payable, % 82135.26 100 25.11 635.37 100 85.02 85.02 85.02 85.02 85.02
Capital Expenditure -.5 -.1 .0 .0 .0 .0 .0 .0 .0 .0
Capital Expenditure, % -15727.3 100 -0.03 -6.33 100 -21.27 -21.27 -21.27 -21.27 -21.27
Tax Rate, % 1.53 1.53 1.53 1.53 1.53 1.53 1.53 1.53 1.53 1.53
EBITAT -33.5 -61.1 -53.8 -85.7 -65.8 .0 .0 .0 .0 .0
Depreciation
Changes in Account Receivables
Changes in Inventories
Changes in Accounts Payable
Capital Expenditure
UFCF -35.3 -74.3 -49.2 -84.1 -63.2 9.4 .0 .0 .0 .0
WACC, % 6.4 6.42 6.42 6.42 6.42 6.41 6.41 6.41 6.41 6.41
PV UFCF
SUM PV UFCF 8.8
Long Term Growth Rate, % 2.00
Free cash flow (T + 1) 0
Terminal Value 0
Present Terminal Value 0
Enterprise Value 9
Net Debt -277
Equity Value 286
Diluted Shares Outstanding, MM 79
Equity Value Per Share 3.61

What You Will Receive

  • Accurate VRNA Financial Data: Pre-loaded with Verona Pharma’s historical and forecasted data for detailed analysis.
  • Customizable Template: Easily adjust key metrics such as revenue growth, WACC, and EBITDA %.
  • Instant Calculations: Watch the intrinsic value of Verona Pharma update in real-time as you make changes.
  • Expert Valuation Tool: Crafted for investors, analysts, and consultants aiming for precise DCF outcomes.
  • Intuitive Design: Clear layout and straightforward instructions suitable for all skill levels.

Key Features

  • Comprehensive DCF Calculator: Offers detailed unlevered and levered DCF valuation models tailored for Verona Pharma plc (VRNA).
  • WACC Calculator: Includes a pre-configured Weighted Average Cost of Capital sheet with adjustable inputs for accurate financial analysis.
  • Customizable Forecast Assumptions: Easily adjust growth rates, capital expenditures, and discount rates to fit your analysis needs.
  • Integrated Financial Ratios: Evaluate profitability, leverage, and efficiency ratios specifically for Verona Pharma plc (VRNA).
  • Interactive Dashboard and Charts: Visual representations provide a clear summary of key valuation metrics for straightforward analysis.

How It Works

  • Download: Obtain the pre-configured Excel file containing Verona Pharma plc's (VRNA) financial data.
  • Customize: Modify projections such as revenue growth, EBITDA %, and WACC according to your analysis.
  • Update Automatically: The intrinsic value and NPV calculations refresh in real-time as you make adjustments.
  • Test Scenarios: Generate various forecasts and instantly compare the results.
  • Make Decisions: Leverage the valuation outputs to inform your investment choices.

Why Choose Verona Pharma plc (VRNA)?

  • Innovative Solutions: Cutting-edge research and development in respiratory diseases.
  • Proven Track Record: Successful clinical trials and a robust pipeline of therapies.
  • Expert Team: A dedicated team of professionals committed to advancing healthcare.
  • Strong Partnerships: Collaborations with leading institutions to enhance drug development.
  • Commitment to Patients: Focused on improving the quality of life for those affected by respiratory conditions.

Who Should Use This Product?

  • Investors: Accurately estimate Verona Pharma plc’s (VRNA) fair value before making investment decisions.
  • CFOs: Utilize a professional-grade DCF model for financial reporting and analysis of Verona Pharma plc (VRNA).
  • Consultants: Quickly adapt the template for valuation reports tailored for clients involving Verona Pharma plc (VRNA).
  • Entrepreneurs: Gain insights into financial modeling practices employed by leading biotech firms like Verona Pharma plc (VRNA).
  • Educators: Use it as a teaching tool to illustrate valuation methodologies relevant to companies such as Verona Pharma plc (VRNA).

What the Template Contains

  • Pre-Filled Data: Includes Verona Pharma plc's historical financials and projections.
  • Discounted Cash Flow Model: Editable DCF valuation model featuring automatic calculations.
  • Weighted Average Cost of Capital (WACC): A dedicated sheet for calculating WACC based on user-defined inputs.
  • Key Financial Ratios: Assess Verona Pharma plc's profitability, efficiency, and financial leverage.
  • Customizable Inputs: Easily modify revenue growth, profit margins, and tax rates.
  • Clear Dashboard: Visual representations and tables summarizing essential valuation outcomes.

No products were found matching.